Genetic Imaging Study With [tc-(99m)] Trodat-1 Spect in Adolescents With Adhd Using Oros-Methylphenidate
| dc.contributor.author | Akay, Aynur Pekcanlar | |
| dc.contributor.author | Kaya, Gamze Capa | |
| dc.contributor.author | Kose, Samet | |
| dc.contributor.author | Yazicioglu, Cigdem Eresen | |
| dc.contributor.author | Erkuran, Handan Ozek | |
| dc.contributor.author | Guney, Sevay Alsen | |
| dc.contributor.author | Oguz, Kaya | |
| dc.date.accessioned | 2023-06-16T14:11:22Z | |
| dc.date.available | 2023-06-16T14:11:22Z | |
| dc.date.issued | 2018 | |
| dc.description.abstract | Aim: To examine theeffects on the brain of 2-month treatment withamethylphenidate extended-release formulation (OROS-MPH) using [Tc-(99m)] TRODAT-1SPECT in a sample of treatment-naive adolescents with Attention Deficit/Hyperactivity Disorder (ADHD). In addition, to assess whether risk alleles (homozygosity for 10-repeat allele at the DAT1 gene were associated with alterations in striatal DAT availability. Methods: Twenty adolescents with ADHD underwent brain single-photon emission computed tomography (SPECT) scans with [Tc-(99m)] TRODAT-1 at baseline and two months after starting OROS-MPH treatment with dosages up to 1 mg/kg/day. Severity of illness was estimated using the Clinical Global Impression Scale (CGI-S) and DuPaul ADHD Rating Scale-Clinician version (ARS) before treatment,1 month and 2 months after initiating OROS-MPH treatment. Results: Decreased DAT availability was found in both the right caudate (pretreatment DAT binding: 224.76 +/- 33.77, post-treatment DAT binding: 208.86 +/- 28.75, p = 0.02) and right putamen (pre-treatment DAT binding: 314.41 +/- 55.24, post-treatment DAT binding: 285.66 +/- 39.20, p = 0.05) in adolescents with ADHD receiving OROS-MPH treatment. Adolescents with ADHD who showed a robust response to OROS-MPH (n = 7) had significantly greater reduction of DAT density in the right putamen than adolescents who showed less robust response to OROS-MPH (n = 13) (p = 0.02). However, between-group differences by treatment responses were not related with DAT density in the right caudate. Risk alleles (homozygosity for the 10-repeat allele of DAT1 gene) in the DAT1 gene were not associated with alterations in striatal DAT availability. Conclusion: Two months of OROS-MPH treatment decreased DAT availability in both the right caudate and putamen. Adolescents with ADHD who showed a robust response to OROS-MPH had greater reduction of DAT density in the right putamen. However,our findings did not support an association between homozygosity for a 10-repeat allele in the DAT1 gene and DAT density, assessedusing[Tc-(99m)] TRODAT-1SPECT. | en_US |
| dc.description.sponsorship | Dokuz Eylul University Research Committee [2008132]; Fogarty MH/DD program; Institute of Nuclear Energy Research (INER-Taipei, Taiwan) | en_US |
| dc.description.sponsorship | This study was partially supported by Dokuz Eylul University Research Committee (2008132), Fogarty MH/DD program and the Institute of Nuclear Energy Research (INER-Taipei, Taiwan). | en_US |
| dc.identifier.doi | 10.1016/j.pnpbp.2018.04.008 | |
| dc.identifier.issn | 0278-5846 | |
| dc.identifier.issn | 1878-4216 | |
| dc.identifier.scopus | 2-s2.0-85046665865 | |
| dc.identifier.uri | https://doi.org/10.1016/j.pnpbp.2018.04.008 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14365/1368 | |
| dc.language.iso | en | en_US |
| dc.publisher | Pergamon-Elsevier Science Ltd | en_US |
| dc.relation.ispartof | Progress in Neuro-Psychopharmacology & Bıologıcal Psychıatry | en_US |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.subject | ADHD | en_US |
| dc.subject | DAT1 gene | en_US |
| dc.subject | [Tc-(99m)] TRODAT-1 SPECT | en_US |
| dc.subject | OROS-methylphenidate | en_US |
| dc.subject | Deficit Hyperactivity Disorder | en_US |
| dc.subject | Dopamine-Transporter Gene | en_US |
| dc.subject | Attention-Deficit/Hyperactivity Disorder | en_US |
| dc.subject | Tc-99m-Trodat-1 Spect | en_US |
| dc.subject | Parkinsons-Disease | en_US |
| dc.subject | Children | en_US |
| dc.subject | Association | en_US |
| dc.subject | Adults | en_US |
| dc.subject | Psychostimulants | en_US |
| dc.subject | Availability | en_US |
| dc.title | Genetic Imaging Study With [tc-(99m)] Trodat-1 Spect in Adolescents With Adhd Using Oros-Methylphenidate | en_US |
| dc.title.alternative | Tc- 99m] Trodat-1 Spect in Adolescents With Adhd Using Oros-Methylphenidate | en_US |
| dc.type | Article | en_US |
| dspace.entity.type | Publication | |
| gdc.author.id | Baykara, Huseyin Burak/0000-0002-1530-0159 | |
| gdc.author.id | Kose, Samet/0000-0003-0841-004X | |
| gdc.author.id | Yazıcıoğlu, Çiğdem Eresen/0000-0001-9155-6589 | |
| gdc.author.id | Erkuran, Handan Özek/0000-0003-3775-0211 | |
| gdc.author.id | Alşen, Sevay/0000-0003-1064-6115 | |
| gdc.author.id | Rohde, Luis Augusto P/0000-0002-4552-4188 | |
| gdc.author.id | Oguz, Kaya/0000-0002-1860-9127 | |
| gdc.author.scopusid | 55667400100 | |
| gdc.author.scopusid | 55662831600 | |
| gdc.author.scopusid | 57536563900 | |
| gdc.author.scopusid | 56251903000 | |
| gdc.author.scopusid | 57192301366 | |
| gdc.author.scopusid | 57194021762 | |
| gdc.author.scopusid | 54902980200 | |
| gdc.author.wosid | Baykara, Huseyin Burak/AAH-4898-2020 | |
| gdc.author.wosid | AKAY, AYNUR/O-7335-2019 | |
| gdc.author.wosid | Yazıcıoğlu, Çiğdem Eresen/P-4539-2019 | |
| gdc.author.wosid | Kose, Samet/Q-2324-2017 | |
| gdc.author.wosid | Erkuran, Handan Özek/G-1490-2019 | |
| gdc.author.wosid | Alşen, Sevay/HJP-9007-2023 | |
| gdc.author.wosid | Rohde, Luis Augusto P/A-6426-2008 | |
| gdc.bip.impulseclass | C5 | |
| gdc.bip.influenceclass | C5 | |
| gdc.bip.popularityclass | C4 | |
| gdc.coar.access | metadata only access | |
| gdc.coar.type | text::journal::journal article | |
| gdc.collaboration.industrial | false | |
| gdc.description.department | İzmir Ekonomi Üniversitesi | en_US |
| gdc.description.departmenttemp | [Akay, Aynur Pekcanlar; Guney, Sevay Alsen; Baykara, Burak; Emiroglu, Neslihan Inal; Miral, Suha] Dokuz Eylul Univ, Dept Child & Adolescent Psychiat, Izmir, Turkey; [Kaya, Gamze Capa; Eren, Mine Sencan; Ertay, Turkan; Durak, Hatice] Dokuz Eylul Univ, Dept Nucl Med, Izmir, Turkey; [Kose, Samet] H Kalyoncu Univ, Dept Psychol, Gaziantep, Turkey; [Kose, Samet] Univ Texas Houston, Med Sch Houston, Ctr Neurobehav Res Addict, Houston, TX USA; [Yazicioglu, Cigdem Eresen; Kizildag, Sefa; Ozsoylu, Dua] Dokuz Eylul Univ, Dept Mol Biol & Genet, Izmir, Turkey; [Erkuran, Handan Ozek] Dr Behcet Uz Pediat Pediat Surg Res & Training Ho, Deparment Child & Adolescent Psychiat, Izmir, Turkey; [Oguz, Kaya] Izmir Univ Econ, Dept Comp Engn, Izmir, Turkey; [Keskin, Duygu; Gonul, Ali Saffet] EgianUniv, Dept Psychiat, Izmir, Turkey; [Rohde, Luis Augusto] Univ Fed Rio Grande do Sul, Dept Psychiat, Porto Alegre, RS, Brazil; [Rohde, Luis Augusto] Hosp Clin Porto Alegre, ADHD Program, Porto Alegre, RS, Brazil | en_US |
| gdc.description.endpage | 300 | en_US |
| gdc.description.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| gdc.description.scopusquality | Q1 | |
| gdc.description.startpage | 294 | en_US |
| gdc.description.volume | 86 | en_US |
| gdc.description.wosquality | Q1 | |
| gdc.identifier.openalex | W2799969460 | |
| gdc.identifier.pmid | 29684537 | |
| gdc.identifier.wos | WOS:000436416800034 | |
| gdc.index.type | WoS | |
| gdc.index.type | Scopus | |
| gdc.index.type | PubMed | |
| gdc.oaire.diamondjournal | false | |
| gdc.oaire.impulse | 3.0 | |
| gdc.oaire.influence | 2.6059934E-9 | |
| gdc.oaire.isgreen | false | |
| gdc.oaire.keywords | Male | |
| gdc.oaire.keywords | Adolescent | |
| gdc.oaire.keywords | OROS-methylphenidate | |
| gdc.oaire.keywords | ADHD | |
| gdc.oaire.keywords | Humans | |
| gdc.oaire.keywords | Genetic Predisposition to Disease | |
| gdc.oaire.keywords | DAT1 gene | |
| gdc.oaire.keywords | [Tc-(99m)] TRODAT-1 SPECT | |
| gdc.oaire.keywords | Psychiatric Status Rating Scales | |
| gdc.oaire.keywords | Tomography, Emission-Computed, Single-Photon | |
| gdc.oaire.keywords | Brain Mapping | |
| gdc.oaire.keywords | Dopamine Plasma Membrane Transport Proteins | |
| gdc.oaire.keywords | Homozygote | |
| gdc.oaire.keywords | Brain | |
| gdc.oaire.keywords | Organotechnetium Compounds | |
| gdc.oaire.keywords | Treatment Outcome | |
| gdc.oaire.keywords | Attention Deficit Disorder with Hyperactivity | |
| gdc.oaire.keywords | Delayed-Action Preparations | |
| gdc.oaire.keywords | Methylphenidate | |
| gdc.oaire.keywords | Central Nervous System Stimulants | |
| gdc.oaire.keywords | Female | |
| gdc.oaire.keywords | Radiopharmaceuticals | |
| gdc.oaire.keywords | Tropanes | |
| gdc.oaire.popularity | 6.340506E-9 | |
| gdc.oaire.publicfunded | false | |
| gdc.oaire.sciencefields | 03 medical and health sciences | |
| gdc.oaire.sciencefields | 0302 clinical medicine | |
| gdc.openalex.collaboration | International | |
| gdc.openalex.fwci | 0.4875 | |
| gdc.openalex.normalizedpercentile | 0.65 | |
| gdc.opencitations.count | 8 | |
| gdc.plumx.crossrefcites | 8 | |
| gdc.plumx.mendeley | 38 | |
| gdc.plumx.pubmedcites | 5 | |
| gdc.plumx.scopuscites | 7 | |
| gdc.scopus.citedcount | 7 | |
| gdc.virtual.author | Oğuz, Kaya | |
| gdc.wos.citedcount | 6 | |
| relation.isAuthorOfPublication | 352071e4-5cb7-4239-be4d-3132ba33986c | |
| relation.isAuthorOfPublication.latestForDiscovery | 352071e4-5cb7-4239-be4d-3132ba33986c | |
| relation.isOrgUnitOfPublication | b4714bc5-c5ae-478f-b962-b7204c948b70 | |
| relation.isOrgUnitOfPublication | 26a7372c-1a5e-42d9-90b6-a3f7d14cad44 | |
| relation.isOrgUnitOfPublication | e9e77e3e-bc94-40a7-9b24-b807b2cd0319 | |
| relation.isOrgUnitOfPublication.latestForDiscovery | b4714bc5-c5ae-478f-b962-b7204c948b70 |
Files
Original bundle
1 - 1 of 1
